#resmetirom

2개의 글

12 de mayo de 2026

MDGL Madrigal Pharmaceuticals Perspectiva 2026: Rezdiffra y la Carrera por el Mercado MASH

Análisis de Madrigal Pharmaceuticals (MDGL) en 2026: ingresos de Rezdiffra de 958 millones en FY2025 y 311 millones en Q1 2026, competencia GLP-1, riesgo del ensayo confirmatorio, cobertura de seguros en LATAM y tesis de adquisición.

MDGL Madrigal Pharmaceuticals Rezdiffra

May 12, 2026

MDGL Madrigal Pharmaceuticals Stock Outlook 2026: Rezdiffra's First-Mover Lead vs. GLP-1 Competition

Madrigal Pharmaceuticals (MDGL) 2026 stock analysis: Rezdiffra revenue trajectory reaching $958M in FY2025 and $311M in Q1 2026, US payer coverage progress, GLP-1 competition dynamics, confirmatory trial risk, and acquisition thesis.

MDGL Madrigal Pharmaceuticals Rezdiffra